Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) will present multiple real‑world poster analyses of vamorolone in Duchenne muscular dystrophy and sponsor an MDA Industry Forum with Santhera at the 2026 MDA Clinical & Scientific Conference in Orlando.
Key events: three poster presentations on March 8, 2026 (6:00–8:00 PM ET) and a sponsored symposium on March 10, 2026 (12:00–1:30 PM ET) in the Hilton Orlando Key Largo Room.
Positive
- None.
Negative
- None.
News Market Reaction – CPRX
On the day this news was published, CPRX declined 0.33%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CPRX is down 1.5% with elevated volume, while highlighted peer ARQT appears in momentum scans moving down without news. Other close peers show mixed, modest moves, suggesting today’s action is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Earnings and guidance | Positive | +2.8% | Record 2025 revenues and 2026 guidance with share repurchase program. |
| Feb 24 | Conference participation | Positive | +0.3% | Announcement of presentation at Barclays Global Healthcare Conference. |
| Feb 11 | Earnings date notice | Neutral | -1.4% | Scheduling of Q4 and full‑year 2025 earnings release and call. |
| Jan 05 | Advocacy summit | Neutral | -1.5% | Inaugural Catalyst Advocacy Scholars Summit with University of Notre Dame. |
| Dec 15 | Conference participation | Positive | +2.4% | Planned presentation at 44th JPM Healthcare Conference with webcast. |
Recent stock reactions have been positive on strong fundamental updates and conference participation, while softer, relationship-building news has seen mixed to slightly negative moves.
Over the past few months, Catalyst reported record 2025 revenues of $589.0 million and launched a $200 million share repurchase program, with that earnings release followed by a 2.77% gain. The company has also highlighted visibility at major conferences such as JPM and Barclays, which produced small positive price reactions. Today’s announcement about DMD real‑world evidence and an MDA symposium builds on this strategy of clinical and scientific engagement around AGAMREE and the Duchenne community.
Market Pulse Summary
This announcement highlights Catalyst’s plans to present multiple real‑world analyses in Duchenne muscular dystrophy and to host a vamorolone‑focused forum at the 2026 MDA conference. The work reinforces AGAMREE’s presence in DMD care and extends clinical dialogue with leading specialists. In context of recent record 2025 financial results and guidance, investors may watch how emerging real‑world data, physician adoption trends, and future regulatory or labeling updates interact with the company’s rare‑disease portfolio.
Key Terms
duchenne muscular dystrophy medical
corticosteroid medical
glucocorticoid medical
AI-generated analysis. Not financial advice.
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals.
“The MDA meeting is a key opportunity to highlight the expanding real‑world evidence shaping care for the Duchenne community,” said Will Andrews, MD, Chief Medical Officer of Catalyst. “Through our poster presentations and our sponsored symposium on long‑term evidence generation, we’re contributing clinical insights that help clarify AGAMREE®’s profile and its role in patient care. Our commitment is to advance rigorous, meaningful research that moves the field forward for patients and their families.”
The poster presentations will focus on real-world analysis of vamorolone in patients living with DMD:
Poster Presentations:
Abstract Title: Real-world analysis of concomitant cardiac medication use with the novel corticosteroid vamorolone in patients with Duchenne muscular dystrophy (DMD)
Authors: Linda Cripe, MD, Nationwide Children's Hospital, Steven Woods, PharmD, Catalyst, Katherine Habkouk, PharmD, AnovoRx Specialty Pharmacy, Regina Grebla, PhD, Northeast Epi, LLC
Session Name: Poster Session
Topic: Clinical Management
Poster Number: 74 S
Date of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET
Abstract Title: Association Between Glucocorticoid Treatment Duration and Health Care Resource Utilization in Duchenne Muscular Dystrophy: A Real-World Analysis.
Authors: Steven Woods, PharmD, Catalyst Pharmaceuticals, Bridget McGowan, MD, Ann and Robert H. Lurie Children's Hospital of Chicago, Ashley Martin, PhD, BluePath Solutions, Alexa Gordon, MS, BluePath Solutions, Sana Mirza, MPH, BluePath Solutions, Paula Alvarez, MBA, MS, Rph, Critical Intelligence Consulting
Session Name: Poster Session
Topic: Other
Poster Number: 75 S
Date of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET
Abstract Title: Glucocorticoid Use and Delayed Respiratory Decline in Duchenne Muscular Dystrophy Patients: A Real-World Analysis
Authors: Steven Woods, PharmD, Catalyst Pharmaceuticals, Bridget McGowan, MD, Ann and Robert H. Lurie Children's Hospital of Chicago, Ashley Martin, PhD, BluePath Solutions, Alexa Gordon, MS, BluePath Solutions, Sana Mirza, MPH, BluePath Solutions, Paula Alvarez, MBA, MS, Rph, Critical Intelligence Consulting, Oscar Mayer, MD, The Children's Hospital of Philadelphia
Session Name: Poster Session
Topic: Other
Poster Number: 76S
Date of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET
MDA Industry Forum will highlight the latest insights from clinical leaders advancing our understanding of DMD:
Symposium:
Title: MDA Industry Forum Sponsored by Catalyst Pharmaceuticals in Conjunction With Santhera Pharmaceuticals
Speakers:
- Dr. Craig McDonald, MD, Chair, Department of Physical Medicine & Rehabilitation Professor, Departments of Pediatrics and Physical Medicine & Rehabilitation UC Davis Health, Sacramento, CA
- Dr. Leanne Ward, MD, Professor of Pediatrics, University of Ottawa, Ottawa, ON
Date of Presentation: Tuesday, March 10, 2026, 12:00 PM-1:30 PM ET
Location: Key Largo Room, The Hilton Orlando
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors described in Catalyst's Annual Report on Form 10-K for the 2025 fiscal year and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Contact Information:
Investor Contact
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
IR@catalystpharma.com
Media Contact
Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC
(646) 249-6817
Ignacio.Guerrero-Ros@russopartnersllc.com
FAQ
What will Catalyst Pharmaceuticals (CPRX) present at the 2026 MDA Clinical & Scientific Conference?
When and where will Catalyst's vamorolone poster presentations (CPRX) be shown at MDA 2026?
What is the MDA Industry Forum sponsored by Catalyst and Santhera about (CPRX)?
Who are the key speakers at the Catalyst‑sponsored MDA Industry Forum (CPRX) and when is it scheduled?
Which specific poster topics will Catalyst (CPRX) cover related to vamorolone in DMD?
